Panc02-Luc Cells
USUSD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | Panc02-Luc is a luciferase-expressing derivative of the Panc02 murine pancreatic adenocarcinoma cell line. Panc02 cells originate from chemically induced pancreatic ductal adenocarcinoma in mice and are widely used as a syngeneic model of pancreatic cancer in immunocompetent murine hosts. The introduction of a luciferase reporter enables highly sensitive bioluminescent imaging of tumor cells in vitro and in vivo, facilitating noninvasive longitudinal monitoring of tumor growth, metastatic dissemination, and therapeutic response. These properties make Panc02-Luc a valuable platform for pancreatic cancer biology, immuno-oncology, and preclinical drug development studies. Panc02-Luc cells are commonly utilized in orthotopic and subcutaneous mouse tumor models to investigate tumor progression, stromal interactions, immune cell infiltration, and mechanisms of resistance to chemotherapy or immunotherapy. Because Panc02 tumors can be established in syngeneic mouse strains with an intact immune system, the model is particularly useful for evaluating checkpoint inhibitors, adoptive cell therapies, cancer vaccines, and combination treatment strategies. Luciferase-based imaging enables repeated quantitative assessment of tumor burden in living animals, reducing experimental variability and supporting real-time evaluation of treatment efficacy. Panc02-Luc cells are used for studies of pancreatic tumor cell proliferation, migration, invasion, cytokine signaling, metabolic adaptation, and apoptosis. The biological behavior of the model may vary depending on the luciferase construct, promoter system, and clonal selection strategy used during engineering. Further characterization data, including reporter stability, luminescence intensity, and metastatic potential, may be important for specialized experimental applications. |
|---|---|
| 生物體 | Mouse |
| 組織 | Pancreas |
| 疾病 | Mouse pancreatic ductal adenocarcinoma |
| 同義詞 | Luciferase Reporter Panc02 Cell Line |
特徵
| 品種/亞種 | C57BL/6 |
|---|---|
| 年齡 | Unspecified |
| 性別 | Male |
| 生長特性 | Adherent |
監管數據
| 引用 | Panc02-Luc (Cytion catalog number 305706) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 10090 |
| Cellosaurus 編號 | CVCL_E3IB |
生物分子資料
| 蛋白質表達 | Luc |
|---|
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS |
| 解離試劑 | Accutase |
| 倍增時間 | 24-48 hours |
| 傳代培養 | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| 播種密度 | 1 to 3 x 104 cells/cm2 |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305706-100426 | 分析證明書 | 15. May. 2026 | 305706 |